16 results about "Spermatocyte" patented technology

The invention relates to the technical field of biological medicines, in particular to an umbilical cord mesenchymal stem cell exosome and application of the umbilical cord mesenchymal stem cell exosome in preparation of a medicine for treating male infertility caused by hidden testis. The prepared high-concentration umbilical cord mesenchymal stem cell exosome suspension preparation is directly used for treating cultured spermatogonial cells and spermatoblasts in vitro, is injected into the testis of a mouse, and is used for improving the seminiferous tubule and spermatogenic microenvironment of testis tissue and promoting division and proliferation of the spermatogonial cells and the spermatoblasts. The method can effectively reverse oligospermia and azoospermia caused by the hidden testis, and compared with a model without intervention of treatment means, the method can effectively promote increase and even regeneration of sperms in the testis.

The invention provides a recombinant lentivirus capable of indicating bovine spermatogonial stem cell differentiation, a spermatogonial stem cell line and application, and belongs to the technical field of cell biology. The invention provides a method for constructing a spermatogonial stem cell line for indicating bovine sperm differentiation on the basis of a lentivirus transduction technology, and a visual detection system for differentiating spermatogonial stem cells into spermatoblasts is constructed by regulating expression of mCherry protein by utilizing a PRM1 promoter. According to the method, the expression of PRM1 is indicated by fluorescent protein mCherry, so that the differentiation process of the bovine spermatogonial stem cells is indicated, and a good tool is provided for the induction of differentiation of the bovine spermatogonial stem cells to sperms, the research of a development mechanism and the optimization of a differentiation system of the bovine spermatogonial stem cells. The method is a new way for solving the neck clamping problem that good-variety bovine sperms are difficult to obtain in scientific research and production, can also be used for optimization of a spermatogonial stem cell differentiation system, sorting and purification of sperms, even downstream research of drug screening and the like, and has a good application prospect.

The application belongs to the technical field of biology, and discloses a method for activating an ASXL2-PRC2 axis, wherein adenovirus is injected into the seminiferous tubule of an organism through an outgoing pipe to activate the expression of endogenous EZH2 and spermatocyte-specific ASXL2 in the organism. The method can be used for reducing impaired sperm motility, increasing sperm penetration and tubulin polymerization, inhibiting abnormal spermatogenesis, down-regulating the transcription level of a TZ marker, increasing the enrichment of SUZ12, EED and H3K27me3 in CEP162 and CEP290 promoters under hypoxic conditions, and slowing down hypoxia-induced abnormal spermatogenesis and spermatocyte activation of the ASXL2-PRC2 axis in the germ cell line of the organism.

The present invention provides a pharmaceutical composition for preventing and treating male infertility. The pharmaceutical composition contains acteoside and echinacoside, wherein the concentration ratio of acteoside to echinacoside is 1 to 4 or 1 / 3. The pharmaceutical composition has the effects of improving male reproductive damage and protecting spermatocytes from the toxicity of environmental estrogen BPA.

The present invention relates to the use of an EPHA inhibitor in inducing meiosis. The EPHA inhibitor can be used to effectively induce the differentiation of undifferentiated spermatogonial cells into spermatocytes, and therefore can be used for the establishment of a model for inducing meiosis in vitro, thus having extremely high application value and clinical significance. Moreover, the EPHA inhibitor does not significantly change the apoptosis level within a dosage of 2 μM-200 μM, such that spermatocytes can be obtained safely and efficiently.

The invention provides development of a spermatogonial-targeting lipid nanomaterial and application of the spermatogonial-targeting lipid nanomaterial in treatment of male infertility, relates to the technical field of biomedicine, and has the technical key points that the lipid nanomaterial and a preparation method thereof are provided, mRNA is delivered to spermatogonial by using the lipid nanomaterial, and the spermatogonial-targeting lipid nanomaterial is prepared by editing the spermatogonial. And edited sperm cells and sperm cells can be obtained. The invention provides an ionizable phospholipid nanoparticle LNP65, which can be injected through a testicular net to effectively transfer mRNA (messenger ribonucleic acid) to spermatogonium in a mouse testis. The spermatogonium has been successfully edited by this method. In one spermatogenic cycle, a modified sperm from a spermatogonial cell edited by LNP65 is obtained. And after three spermatogenesis cycles, observing that the spermatogonium cells edited by the LNP65 are cleared from the testis. The invention develops a lipid nanomaterial delivery mRNA (messenger Ribonucleic Acid) system of targeted spermatogonium, and provides an applicable carrier for treating azoospermia caused by single gene deletion.

The application belongs to the technical field of biological medicine, and particularly relates to application of a reagent for inhibiting PPAR alpha expression in preparation of a medicine for treating male infertility diseases, wherein a PPAR alpha inhibitor (GW6471) or an active oxygen scavenger (NAC) is given to male mice exposed to cadmium water, it is found that the number of sperm in a Cd+GW6471 group is higher than that in a Cd+NAC group, the serum testosterone level in the Cd+GW6471 group is also higher than that in the Cd+NAC group, and the results of testicular tissue pathological staining also show that GW6471 can more significantly restore the decrease in the number of mature spermatogenic tubules caused by Cd, GW6471 restores the decrease in the number of SYCP3 positive spermatocytes caused by Cd, so that the sperm production efficiency is restored, and therefore the application of the reagent for inhibiting PPAR alpha expression in preparation of the medicine for treating male infertility diseases is proposed.

The invention discloses application of lycium barbarum red in treating male reproductive toxicity, and belongs to the technical field of biological medicine. The invention provides application of lycium barbarum red in preparation of a medicine for treating male reproductive toxicity. The male reproductive toxicity is caused by exposure to benzophenone substances or exposure to diethylstilbestrol. Animal experiments find that the lycium barbarum red can effectively improve testis function damage induced by benzophenone substance BP-3 or estrogen diethylstilbestrol, improve seminiferous tubule damage degree, increase seminiferous epithelium height, increase sperm number, spermatogonium and primary spermatoblasts, improve spermatogenic ability, increase pregnancy rate, improve sperm yield, improve sperm quality and improve sperm quality. The growth and development of offspring are promoted.

The invention discloses a pharmaceutical composition consisting of cistanche, prepared rehmannia root, schisandra chinensis and semen cuscutae, wherein the mass ratio of the cistanche to the prepared rehmannia root to the schisandra chinensis to the semen cuscutae is (2-6): (1-5): (1-4): (0.1-2). In in-vivo experiments of SD rats with oligoasthenospermia induced by tripterygium glycosides, the pharmaceutical composition disclosed by the invention can be used for remarkably increasing sperm quantity, sperm motility and sperm motility rate, reducing sperm malformation rate, partially reversing pathological changes of testis and epididymis tissues, improving ultrastructural damage of spermatogonium cells, repairing spermatogonium stem cell (SSCs) pools, and improving the curative effect of the spermatogonium cells. The levels of various sex hormones are callback to be normal. The pharmaceutical composition of the present invention has been demonstrated to promote spermatogenesis by acting on the source of spermatogenesis-SSCs and on the start of meiosis-spermatoblasts (GC-2).

The invention relates to the field of teaching aids, and provides a meiosis teaching demonstration model, in which a demonstration board is used as a demonstration substrate, and a genetic material clip is used in cooperation to form a chromosome model. Two groups of power devices (including an adsorption end I, a power end I, an elastic connecting rope, an adsorption end II, a power end II and an elastic connecting rope) are utilized to display the whole process that primary sperm cells are split twice to form four sperm cells, and in addition, after chromosome migration is completed, the power end I and the elastic connecting rope as well as the power end II and the elastic connecting rope are separated into four sperm cells. According to the model, two cell division processes can be continuously completed on the same demonstration board, the whole meiosis process is visual, continuous and simple and convenient to operate, the difficulty of understanding of students is greatly reduced, and meanwhile, the students can participate manually in the whole process, so that the purposes of teaching through lively activities and conveniently achieving demonstration teaching are achieved.

The present disclosure relates to an application of hydrogen molecules in the preparation of a product for promoting stem cell activation. Various hydrogen intervention means and generation means may be adopted when hydrogen molecules are applied, promoting the activation of autologous stem cells such as epidermal stem cells, basal stem cells, hair follicle stem cells, bone marrow-derived stem cells, mesenchymal stem cells, spermatocytes and neural stem cells. The related content may be applied to various fields such as wound healing, tissue / organ repair, tumor treatment, nervous system disease treatment, infertility treatment and aesthetic medicine.

The present invention, generally speaking, relates to methods of contraception in male subjects, which may be a human or a non-human mammal. The present inventors have surprisingly found that the zona pellucida (ZP) proteins, especially the zona pellucida 3 protein (ZP3), is expressed in spermatogonia, spermatocytes and round and elongated spermatids of human and mouse testis, but absent in mature spermatozoa, Sertoli, Leydig, spermatogonial stem and progenitor cells. Based on these findings, zona pellucida proteins, in particular ZP3, constitute suitable targets for immunocontraceptive strategies, especially strategies aimed at inducing transient and reversible male infertility.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a reagent for inhibiting PPARalpha expression in preparation of a medicine for treating male infertility diseases, a PPARalpha inhibitor (GW6471) or an active oxygen scavenger (NAC) is given to male mice exposed to cadmium water, it is found that the sperm number of a Cd + GW6471 group is higher than that of a Cd + NAC group, the serum testosterone level of the Cd + GW6471 group is also higher than that of the Cd + NAC group, and the PPARalpha inhibitor (GW6471) or the active oxygen scavenger (NAC) is applied to the male mice exposed to cadmium water. The result of pathological staining of the testis tissue also shows that the GW6471 can more obviously recover the reduction of the number of mature seminiferous tubules caused by Cd, and the GW6471 recovers the phenomenon of reduction of the number of SYCP3 positive spermatocytes caused by Cd, so that the spermatogenesis efficiency is recovered, and the spermatogenesis effect is improved. Therefore, the invention provides the application of the reagent for inhibiting the expression of the PPARalpha in preparing the medicine for treating the male infertility disease.

The invention relates to the field of animal models, in particular to a construction method and application of a male germ cell specific Agk knockout mouse model, and an Agkflox / flox mouse and a Stra8-Cre mouse are mated to obtain the male germ cell specific Agk knockout mouse model (Agk-CKO). The invention constructs a male germ cell specific Agk conditional knockout mouse model, and finds that the specific knockout of the Agk gene in the male germ cell leads to sterility, testicular development and spermatogenesis abnormality of an Agk-CKO adult male mouse, and the Agk-CKO spermatoblasts show abnormal cell state and damaged subsequent differentiation ability from the fine line phase. The animal model disclosed by the invention can be used for researching the regulation and control mechanism of the development and differentiation state and meiosis of male germ cells, and is expected to provide a new thought and a treatment target for clinical diagnosis and treatment and drug research and development of male infertility.

The application belongs to the technical field of animal models, and provides a method for constructing a mouse testis tissue stress granule animal model, which comprises the following steps: after the mouse is anesthetized, the testis and epididymis of one side of the mouse are taken out; a sodium arsenite solution containing fast green dye is injected into the testis of the mouse through the entrance of the rete testis, and the concentration of the sodium arsenite solution is 30-50 mM; the wound of the mouse is sutured, the mouse is killed after the mouse recovers for 3 hours, and the testis tissue is separated for an immunofluorescence experiment; when obvious stress granules are formed, it is indicated that the model construction is successful. The application also provides an application of the method for constructing an animal model in identifying the generation of stress granules of spermatocytes and in identifying the generation of RNA binding protein SERBP1. The application provides a method for exploring the role of SERBP1 protein in the stress granules of the mouse testis tissue, a related mechanism and a possible molecular pathway, and provides a new theoretical basis for guiding the generation and recovery of cell stress granules under special conditions.

The present invention provides methods for diagnosing or predicting fertility defects, such as infertility, in a mammalian male individual by detecting RPN1. The invention also provides kits and instruments for diagnosing or predicting fertility defects, such as infertility disorders, in mammalian male individuals by detecting RPN1. The invention discovers and proves for the first time that knockout of RPN1 can cause meiosis abnormality and complete sterility of spermatoblasts of male mice due to the fact that the glycosylation level of mitochondrial related proteins is remarkably reduced due to deletion of RPN1, and then the structure and function of mitochondria are affected. The invention provides a method for diagnosing male fertility defects of mammals including human beings, and provides a new thought and method for developing new treatment for male infertility individuals influenced by gene mutation.